These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 19414383)

  • 21. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
    Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S
    Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
    Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
    J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of antitumor activity of gefitinib in pediatric glioblastoma and neuroblastoma cells.
    Hatziagapiou K; Braoudaki M; Karpusas M; Tzortzatou-Stathopoulou F
    Clin Lab; 2011; 57(9-10):781-4. PubMed ID: 22029196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
    Park JJ; Yi JY; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
    Biochem Pharmacol; 2012 Apr; 83(7):849-57. PubMed ID: 22266356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
    Jones HE; Goddard L; Gee JM; Hiscox S; Rubini M; Barrow D; Knowlden JM; Williams S; Wakeling AE; Nicholson RI
    Endocr Relat Cancer; 2004 Dec; 11(4):793-814. PubMed ID: 15613453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
    Donfrancesco A; De Ioris MA; McDowell HP; De Pasquale MD; Ilari I; Jenkner A; Castellano A; Cialfi S; De Laurentis C; Dominici C
    Pediatr Blood Cancer; 2010 Jan; 54(1):55-61. PubMed ID: 19821523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
    Mantha AJ; Hanson JE; Goss G; Lagarde AE; Lorimer IA; Dimitroulakos J
    Clin Cancer Res; 2005 Mar; 11(6):2398-407. PubMed ID: 15788691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenomatous polyposis coli determines sensitivity to the EGFR tyrosine kinase inhibitor gefitinib in colorectal cancer cells.
    Zhang Y; Xiao Q; Zhang H; Sun X; Ge H; Liu X; Guan L; Sun M
    Oncol Rep; 2014 Apr; 31(4):1811-7. PubMed ID: 24573033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
    Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gefitinib inhibits sodium phosphate co-transporter III isoform 1 in a model of human malignant glioma.
    Puech C; Prevot N; Perek N
    Anticancer Res; 2014 Nov; 34(11):6527-35. PubMed ID: 25368255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
    Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
    Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway.
    Lu PH; Kuo TC; Chang KC; Chang CH; Chu CY
    Br J Dermatol; 2011 Jan; 164(1):38-46. PubMed ID: 20846305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
    Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
    Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines.
    Lopez JP; Wang-Rodriguez J; Chang CY; Sneh G; Yu MA; Pardo FS; Aguilera J; Ongkeko WM
    Laryngoscope; 2008 Aug; 118(8):1372-6. PubMed ID: 18475209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
    Kobayashi S; Ji H; Yuza Y; Meyerson M; Wong KK; Tenen DG; Halmos B
    Cancer Res; 2005 Aug; 65(16):7096-101. PubMed ID: 16103058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.